Here we present research on an ultra-luminous X-ray source （ULX） candidate 2XMM J 140229.91＋542118.8. The X-ray light curves of this ULX candidate in M 101 exhibit features of a flare star. More importantly, the Ch...Here we present research on an ultra-luminous X-ray source （ULX） candidate 2XMM J 140229.91＋542118.8. The X-ray light curves of this ULX candidate in M 101 exhibit features of a flare star. More importantly, the Chandra light curve displays unusual X-ray double flares, which is comprised of two close peaks. The X-ray （0.3-11.0 keV） flux of the first peak was derived from the two-temperature APEC model as ～ 1.1 ±0.1× 10-12 ergcm-2 s-1. The observed flux at its first peak increased by about two orders of magnitude in X-ray as compared to quiescence. The slope of the second fast decay phase is steeper than the slope of the first fast decay phase, indicating that the appearance of a second flare accelerated the cooling of the first flare in a way we do not understand yet. We also observed its optical counterpart using a 2.16 m telescope administered by National Astronomical Observatories, Chinese Academy of Sciences. By optical spectral fitting, it is confirmed to be a late type dMe2.5 star. According to the spectral type and apparent magnitude of its optical counterpart, we estimate the photometric distance to be ～ 133.4 ±14.2 pc. According to the X-ray spectral fitting, a possible explanation is provided. However, more similar close double flares are needed to confirm whether this accelerated cooling event is a unique coincidence or a common physical process during double flaring.展开更多
The tumor selectivity of alkylating agents that produce guanine O6-chloroethyl (laromustine and carmustine) and O6-methyl (temozolomide) lesions depends upon O6-methylguanine-DNA methyltransferase (MGMT) activity bein...The tumor selectivity of alkylating agents that produce guanine O6-chloroethyl (laromustine and carmustine) and O6-methyl (temozolomide) lesions depends upon O6-methylguanine-DNA methyltransferase (MGMT) activity being lower in tumor than in host tissue. Despite the established role of MGMT as a tumor resistance factor, consensus on how to assess MGMT expression in clinical samples is unsettled. The aim of this study is to examine the relationship between the values derived from distinctive MGMT measurements in 13, 12, 6 and 2 pairs of human tumors and matched normal adjacent tissue from the colon, kidney, lung and liver, respectively, and in human cell lines. The MGMT measurements included 1) alkyl-transfer assays using [benzene-3H]O6-benzylguanine as a substrate to assess functional MGMT activity, 2) methylation-specific PCR (MSP) to probe MGMT gene promoter CpG methylations as a measure of gene silencing, and 3) western immunoblots to analyze the MGMT protein. In human cell lines, a strict negative correlation existed between MGMT activity and the extent of promoter methylation. In tissue specimens, by contrast, the correlation between these two variables was low. Moreover, alkyl-transfer assays identified 3 pairs of tumors and normal tissue with tumor-selective reduction in MGMT activity in the absence of promoter methylation. Cell line MGMT migrated as a single band in western analyses, whereas tissue MGMT was heterogeneous around its molecular size and at much higher molecular masses, indicative of multi-layered post-translational modifications. Malignancy is occasionally associated with a mobility shift in MGMT. Contrary to the prevalent expectation that MGMT expression is governed at the level of gene silencing, these data suggest that other mechanisms that can lead to tumorselective reduction in MGMT activity exist in human tissue.展开更多
基金the National Natural Science Foundation of China(NSFC)under grants 11333004 and11403056
文摘Here we present research on an ultra-luminous X-ray source （ULX） candidate 2XMM J 140229.91＋542118.8. The X-ray light curves of this ULX candidate in M 101 exhibit features of a flare star. More importantly, the Chandra light curve displays unusual X-ray double flares, which is comprised of two close peaks. The X-ray （0.3-11.0 keV） flux of the first peak was derived from the two-temperature APEC model as ～ 1.1 ±0.1× 10-12 ergcm-2 s-1. The observed flux at its first peak increased by about two orders of magnitude in X-ray as compared to quiescence. The slope of the second fast decay phase is steeper than the slope of the first fast decay phase, indicating that the appearance of a second flare accelerated the cooling of the first flare in a way we do not understand yet. We also observed its optical counterpart using a 2.16 m telescope administered by National Astronomical Observatories, Chinese Academy of Sciences. By optical spectral fitting, it is confirmed to be a late type dMe2.5 star. According to the spectral type and apparent magnitude of its optical counterpart, we estimate the photometric distance to be ～ 133.4 ±14.2 pc. According to the X-ray spectral fitting, a possible explanation is provided. However, more similar close double flares are needed to confirm whether this accelerated cooling event is a unique coincidence or a common physical process during double flaring.
文摘The tumor selectivity of alkylating agents that produce guanine O6-chloroethyl (laromustine and carmustine) and O6-methyl (temozolomide) lesions depends upon O6-methylguanine-DNA methyltransferase (MGMT) activity being lower in tumor than in host tissue. Despite the established role of MGMT as a tumor resistance factor, consensus on how to assess MGMT expression in clinical samples is unsettled. The aim of this study is to examine the relationship between the values derived from distinctive MGMT measurements in 13, 12, 6 and 2 pairs of human tumors and matched normal adjacent tissue from the colon, kidney, lung and liver, respectively, and in human cell lines. The MGMT measurements included 1) alkyl-transfer assays using [benzene-3H]O6-benzylguanine as a substrate to assess functional MGMT activity, 2) methylation-specific PCR (MSP) to probe MGMT gene promoter CpG methylations as a measure of gene silencing, and 3) western immunoblots to analyze the MGMT protein. In human cell lines, a strict negative correlation existed between MGMT activity and the extent of promoter methylation. In tissue specimens, by contrast, the correlation between these two variables was low. Moreover, alkyl-transfer assays identified 3 pairs of tumors and normal tissue with tumor-selective reduction in MGMT activity in the absence of promoter methylation. Cell line MGMT migrated as a single band in western analyses, whereas tissue MGMT was heterogeneous around its molecular size and at much higher molecular masses, indicative of multi-layered post-translational modifications. Malignancy is occasionally associated with a mobility shift in MGMT. Contrary to the prevalent expectation that MGMT expression is governed at the level of gene silencing, these data suggest that other mechanisms that can lead to tumorselective reduction in MGMT activity exist in human tissue.
